Research and Development

Less than a decade after the company was suspended, Roche has now successfully re-joined the Association of the British Pharmaceutical …

Packaging Equipment Specialist, Sepha, has released a functional upgrade for one of its original products, EZ Blister, the lab scale …

 Originally published in the September edition of Pharmafocus, Matt Fellows investigates how cloud computing may just be the answer the …

Eli Lilly has elected Jamere Jackson to its board of directors, effective 1 October, where he will serve on the …

News has emerged that Novartis plans to close down its Cell and Gene Therapies unit, with up to 120 workers …

Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …

Recipharm, the contract development and manufacturing organisation (CDMO), announces that it has entered into a long term supply agreement with …

The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …

According to US regulators, AstraZeneca is to pay $5.52 million to resolve a foreign bribery probe investigating payments made to …

Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …

Teva is currently in the process of winding down operations at its manufacturing plant in Pomona, New York as it …

The University of Edinburgh has released a report that claims UK health service spending on asthma has reached £1.1 billion …

Two months after small drugmaker KaloBios returns from bankruptcy, controversial industry figure Martin Shkreli is no longer a stakeholder in …

The number of drugs currently in development to combat heart disease has fallen in the last 20 years, it has …

Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …